INT351371

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.34
Pain Relevance 0.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Mir470 (Mus musculus)
Pain Link Frequency Relevance Heat
Cancer pain 23 63.36 Quite High
Nerve growth factor 25 58.80 Quite High
Pain 30 54.20 Quite High
allodynia 2 51.28 Quite High
Hyperalgesia 1 50.84 Quite High
Breakthrough pain 1 35.80 Quite Low
Thermal hyperalgesia 1 25.52 Quite Low
sodium channel 2 25.44 Quite Low
Inflammation 6 20.08 Low Low
Analgesic 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Sarcoma 8 88.80 High High
Cancer 55 87.52 High High
Cancer Pain 11 63.36 Quite High
Neuropathic Pain 2 51.28 Quite High
Hyperalgesia 3 50.84 Quite High
Neuroma 25 50.00 Quite Low
Bone Cancer 13 50.00 Quite Low
Pain 31 35.80 Quite Low
INFLAMMATION 6 20.08 Low Low
Malignant Neoplastic Disease 1 11.96 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The Trk inhibitor (ARRY-470; Array BioPharma, Boulder, CO) is a potent inhibitor of the tropomyosin kinase family of neurotrophin receptors, demonstrating nanomolar cellular inhibition of TrkA (6.5 nM), TrkB (8.1 nM), and TrkC (10.6 nM) and a high level of selectivity over a panel of kinases run at the ATP Km at 1.0 uM and non-kinase receptors [48](Additional file 1 Table S1 and S2).
Negative_regulation (inhibitor) of ARRY-470
1) Confidence 0.01 Published 2010 Journal Mol Pain Section Body Doc Link PMC3004846 Disease Relevance 0.34 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox